v3.26.3
Investment in Equity Securities (Tables)
9 Months Ended
Sep. 30, 2026
Investment in Equity Securities [Abstract]  
Schedule of Converted Basis Using The Quoted Price of Glucotrack Common Stock The Series A preferred stock had not been issued to the Company as of September 30, 2026 and is measured on an as-converted basis using the quoted price of Glucotrack common stock.

 

    Investment in Glucotrack  
Fair value at July 14, 2026   $ 962,935  
Change in fair value — three months ended September 30, 2026     (710,705 )
Balance at September 30, 2026   $ 252,230